Literature DB >> 3771622

Enhancement of the in vitro cytotoxicity of bouvardin by verapamil alone and combined with hyperthermia in Sarcoma 180 and Ehrlich ascites carcinoma cells.

M P Chitnis, M K Adwankar.   

Abstract

The cytotoxic effect of bouvardin (BVD) a protein synthesis inhibitor was studied separately and in combination with verapamil (VRP), a vasodilator and hyperthermia (43 degrees C) against Sarcoma 180 (S 180) and Ehrlich ascites carcinoma (EAC) tumour cells in vitro. S 180 cells exhibited natural resistance to hyperthermia and BVD, whereas EAC tumour cells were found to be sensitive. VRP alone did not show cytotoxicity to either tumour cells. A combination of BVD and VRP at an elevated temperature resulted in a greater cell kill in the EAC tumour cell line whereas the natural resistance of S 180 tumour cells to the drug BVD and hyperthermia was circumvented by combination with VRP. Combination of BVD, hyperthermia and VRP resulted in greater cell kill, compared to separate treatment with the single agents. The cytotoxicity was evaluated by comparing the inhibition of incorporation of 3H-thymidine in treated cells to that in untreated cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3771622     DOI: 10.1007/bf00404395

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  Rapid membrane filtration technics for studying the action of 6-thioguanine on tumor cells in vitro.

Authors:  F U BROWN; M KLEIN; T S KANDASWAMY; H G MANDEL
Journal:  Cancer Res       Date:  1963-02       Impact factor: 12.701

Review 2.  Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.

Authors:  T C Hamilton; R C Young; R F Ozols
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

3.  Clinical studies with ultrasound-induced hyperthermia.

Authors:  J B Marmor; D Pounds; G M Hahn
Journal:  Natl Cancer Inst Monogr       Date:  1982-06

4.  Biochemical parameters of resistance of an adriamycin-resistant subline of P388 leukemia to emetine, an inhibitor of protein synthesis.

Authors:  M P Chitnis; R K Johnson
Journal:  J Natl Cancer Inst       Date:  1978-05       Impact factor: 13.506

5.  Bouvardin and deoxybouvardin, antitumor cyclic hexapeptides from Bouvardia ternifolia (Rubiaceae).

Authors:  S D Jolad; J J Hoffmann; S J Torrance; R M Wiedhopf; J R Cole; S K Arora; R B Bates; R L Gargiulo; G R Kriek
Journal:  J Am Chem Soc       Date:  1977-11-23       Impact factor: 15.419

6.  Natural thermal resistance of human tumor cells and the role of prostaglandin.

Authors:  F K Storm; D J Roe; S Hildebrand-Zanki; G D Worth; D L Morton; D H Kern
Journal:  Surgery       Date:  1983-08       Impact factor: 3.982

7.  Prediction of the response to chemotherapy in acute leukemia by a short-term test in vitro.

Authors:  J D Schwarzmeier; E Paietta; K Mittermayer; R Pirker
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

8.  In vitro enhancement of adriamycin cytotoxicity in human myeloid leukemia cells exposed to verapamil.

Authors:  S G Pradhan; V S Basrur; M P Chitnis; S H Adwani
Journal:  Oncology       Date:  1984       Impact factor: 2.935

9.  Potentiation of vincristine and Adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1983-05       Impact factor: 12.701

10.  Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells.

Authors:  A Ramu; R Spanier; H Rahamimoff; Z Fuks
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

View more
  1 in total

1.  Anticancer effects of 6-o-palmitoyl-ascorbate combined with a capacitive-resistive electric transfer hyperthermic apparatus as compared with ascorbate in relation to ascorbyl radical generation.

Authors:  Shinya Kato; Ryoko Asada; Katsuhiro Kageyama; Yasukazu Saitoh; Nobuhiko Miwa
Journal:  Cytotechnology       Date:  2011-06-11       Impact factor: 2.058

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.